Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fusobacterium nucleatum is a Gram-negative, anaerobic bacterium that serves as a key structural component of oral biofilms, acting as a bridge between early and late colonizers (Kolenbrander et al., 2000, PubMed: 11133480). While a common inhabitant of the human oral cavity, it is a primary pathogen in periodontal diseases and has been increasingly implicated in systemic conditions, most notably colorectal cancer, where it promotes tumor progression and chemoresistance via its FadA adhesin and Fap2 protein (Kostic et al., 2012, PubMed: 22012620; Han et al., 2005, PubMed: 15713475). Other oral pathogens often associated with it include the Red Complex (Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola), which collectively drive chronic inflammation and tissue destruction (Socransky et al., 1998, PubMed: 9722696). Therapeutic strategies targeting these organisms typically involve broad-spectrum or targeted antibiotics and antiseptics that disrupt bacterial cell walls, DNA replication, or protein synthesis (StatPearls, 2023). However, the challenge remains to selectively eliminate these pathogens without inducing widespread dysbiosis in the host microbiome (PubMed: 30333462).
Inhibition of bacterial DNA synthesis, cell wall synthesis, or protein synthesis; disruption of biofilm integrity and bacterial adhesion (StatPearls, 2023; PubMed: 11133480).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fusobacterium nucleatum and other oral pathogens (F. nucleatum).